abstract of the disclosure [0112] the present invention relates to methods and compositions for preventing and treating staphylococcus aureus in a subject. therapeutic compositions of the present invention comprising leukocidin and and / or d proteins or polypeptides and anti-leukocidin and and / or d antibodies. the invention further relates to methods of identifying inhibitors of luke / d cytotoxicity and inhibitors of luke / d-leukocyte binding. "methods for treating and preventing staphylococcus aureus infections and associated conditions". The present invention relates to methods and compositions for preventing and treating staphylococcus aureus in a subject. Therapeutic compositions of the present invention comprise leucocidin proteins and polypeptides and and / or d and anti-leucocidin antibodies and / or d. The invention further relates to methods for identifying luke / d cytotoxicity inhibitors and luke / d-leukocyte binding inhibitors.abstract of the disclosure [0112] the present invention relates to methods and compositions for preventing and treating staphylococcus aureus in a subject. therapeutic compositions of the present invention comprise leukocidin e and/or d proteins or polypeptides and anti-leukocidin e and/or d antibodies. the invention further relates to methods of identifying inhibitors of luke/d cytotoxicity and inhibitors of luke/d-leukocyte binding. tradução: resumo patente de invenção: "métodos para tratar e prevenir infecções por staphylococcus aureus e condições associadas". a presente invenção se refere a métodos e composições para prevenir e tratar staphylococcus aureus em um sujeito. composições terapêuticas da presente invenção compreendem proteínas ou polipeptídeos de leucocidina e e/ou d e anticorpos anti-leucocidina e/ou d. a invenção ainda se refere a métodos para identificar inibidores de citotoxicidade de luke/d e inibidores de ligação de luke/d-leucócito.
